Reviva Pharmaceuticals (NASDAQ:RVPH) Releases Earnings Results, Beats Expectations By $0.07 EPS

Reviva Pharmaceuticals (NASDAQ:RVPH) issued its quarterly earnings data on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports.

Reviva Pharmaceuticals Stock Performance

NASDAQ RVPH traded down $0.06 during trading hours on Monday, hitting $0.95. 804,477 shares of the company traded hands, compared to its average volume of 1,066,697. The stock has a market capitalization of $31.90 million, a price-to-earnings ratio of -0.86 and a beta of -0.09. Reviva Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.28. The business’s 50-day moving average is $1.53 and its 200-day moving average is $1.47.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on RVPH shares. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Friday, January 10th. HC Wainwright lowered their price target on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Finally, Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $11.40.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.